股本结构
单位：万股
| 公告日期 | 2024-04-16 | 2024-03-28 | 2024-04-02 | 2024-02-15 | 2023-11-13 | 2023-11-13 |
|---|---|---|---|---|---|---|
| 证券总股本 | 158.43 | 142.46 | 123.16 | 89.24 | 1249.43 | 485.85 |
| 普通股本 | 158.43 | 142.46 | 123.16 | 89.24 | 1249.43 | 485.85 |
| 优先股 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 其他 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 变动日期 | 2024-03-31 | 2024-03-28 | 2024-03-22 | 2024-02-20 | 2023-11-08 | 2023-09-30 |
注释：中概股证券总股本=普通股股本/
存托凭证比例
历史变动
| 公告日期 | 变动后普通股本（万股） | 变动后优先股（万股） | 变动原因 | 变动日期 |
|---|---|---|---|---|
| 2024-04-16 | 158.43 | 未披露 | 定期报告 | 2024-03-31 |
| 2024-03-28 | 142.46 | 未披露 |
更多>>
Common stock offered 193,000 shares by the company
|
2024-03-28 |
| 2024-04-02 | 123.16 | 未披露 | 定期报告 | 2024-03-22 |
| 2024-02-15 | 89.24 | 未披露 |
更多>>
Vaccinex, Inc. announced that it will effect a 1-for-14 reverse stock split of its issued common stock, effective at 5:00 p.m. Eastern Time on Monday, February 19, 2024. Beginning Tuesday, February 20, 2024, the Company's common stock will trade on a split-adjusted basis.
|
2024-02-20 |
| 2023-11-13 | 1249.43 | 未披露 | 定期报告 | 2023-11-08 |
| 2023-10-02 | 1199.61 | 未披露 |
更多>>
Common stock offered 7,600,000 share by the company
|
2023-10-02 |
| 2023-11-13 | 485.85 | 未披露 |
更多>>
From June 30, 2023 to September 30, 2023
Issuance of Common Shares
|
2023-09-30 |
| 2023-09-22 | 439.61 | 未披露 |
更多>>
On September 22, 2023, Vaccinex, Inc. (the “Company”) filed a Certificate of Amendment (the “Amendment”) to the Company’s Amended and Restated Certificate of Incorporation, with the Delaware Secretary of State to implement a reverse stock split of the Company’s issued shares of common stock at a ratio of 1-for-15, effective at 5:00 p.m. Eastern Time on September 25, 2023 (the “Reverse Stock Split”).s
|
2023-09-26 |
| 2023-08-14 | 6594.11 | 未披露 | 定期报告 | 2023-08-08 |
| 2023-08-14 | 6566.84 | 未披露 |
更多>>
From March 31, 2023 to June 30, 2023
Issuance of Common Shares
|
2023-06-30 |
| 2023-06-14 | 6535.06 | 未披露 | 定期报告 | 2023-06-06 |
| 2023-05-15 | 5485.64 | 未披露 |
更多>>
From January 1, 2023 to March 31, 2023
Issuance of Common Shares
|
2023-03-31 |
| 2023-03-31 | 4988.08 | 未披露 | 定期报告 | 2023-03-24 |
| 2023-01-24 | 4988.09 | 未披露 | 定期报告 | 2023-01-11 |
| 2023-03-31 | 4988.08 | 未披露 |
更多>>
From December 31, 2021 to December 31, 2022
Issuance of common shares
|
2022-12-31 |
| 2022-11-14 | 4271.90 | 未披露 | 定期报告 | 2022-11-09 |
| 2022-03-31 | 4266.41 | 未披露 | 定期报告 | 2022-03-25 |
| 2021-08-16 | 3080.11 | 未披露 |
更多>>
From March 31, 2021 to June 30, 2021
Exchange of partnership units for common shares
|
2021-06-30 |
| 2021-05-17 | 2845.06 | 未披露 | 定期报告 | 2021-05-12 |
| 2021-05-17 | 2844.50 | 未披露 |
更多>>
From January 1, 2021 To March 31, 2021
Issuance of Common Shares
Shares issued for compensation
Exchange of VX3 Units for common shares
|
2021-03-31 |
| 2021-03-31 | 2844.11 | 未披露 | 定期报告 | 2021-03-26 |
| 2021-03-31 | 2238.72 | 未披露 |
更多>>
From December 31, 2019 to December 31, 2020
Issuance of Common Shares
Exchange of Vaccinex Products LP Units for common shares
Stock-based compensation
Exercise of stock options
|
2020-12-31 |
| 2020-11-13 | 2238.56 | 未披露 | 定期报告 | 2020-11-10 |
| 2020-11-13 | 2237.95 | 未披露 |
更多>>
From June 30, 2020 to September 30, 2020
Issuance of common shares
Exchange of Vaccinex Products LP Units for common shares
Exercise of stock options
|
2020-09-30 |
| 2020-08-14 | 2009.42 | 未披露 | 定期报告 | 2020-08-14 |
| 2020-08-14 | 2001.72 | 未披露 | 定期报告 | 2020-08-13 |
| 2020-08-14 | 1702.30 | 未披露 |
更多>>
From March 31, 2020 to June 30, 2020
Issuance of common shares
Exchange of Vaccinex Products LP Units for common shares
|
2020-06-30 |
| 2020-05-14 | 1664.46 | 未披露 | 定期报告 | 2020-05-08 |
| 2020-05-14 | 1637.67 | 未披露 |
更多>>
From January 1, 2020 to March 31, 2020
Issuance of Common Shares
Stock-based compensation
Exercise of stock options
|
2020-03-31 |
| 2020-04-08 | 1635.67 | 未披露 | 定期报告 | 2020-03-26 |
| 2020-03-09 | 1635.62 | 未披露 | 定期报告 | 2020-03-05 |
| 2020-02-13 | 1635.57 | 未披露 | 定期报告 | 2020-02-07 |
| 2020-03-09 | 1488.71 | 未披露 |
更多>>
from December 31, 2018 to December 31, 2019
Issuance of Common Shares
Conversion of Vaccinex Products LP Units into common shares
|
2019-12-31 |
| 2019-11-12 | 1486.25 | 未披露 | 定期报告 | 2019-11-08 |
| 2019-11-12 | 1148.02 | 未披露 |
更多>>
from June 30, 2019 to September 30, 2019
Issuance of Common Shares
|
2019-09-30 |
| 2019-08-14 | 1486.25 | 未披露 | 定期报告 | 2019-08-14 |
| 2019-08-14 | 1148.02 | 未披露 |
更多>>
from March 31, 2019 to June 30, 2019
Conversion of Vaccinex Products LP Units into common shares
|
2019-06-30 |
| 2019-05-15 | 1147.88 | 未披露 | 定期报告 | 2019-05-10 |
| 2018-11-13 | 1147.57 | 未披露 |
更多>>
from December 31, 2017 to September 30, 2018
Conversion of redeemable convertible preferred stock (Series B, B-1, B-2, C, D) to common stock
Conversion of convertible preferred stock (Series A) to common stock
Initial public offering, net of issuance costs of $5,551
Exercise of stock options
|
2018-09-30 |
| 2018-08-14 | 1147.57 | 未披露 | 定期报告 | 2018-08-14 |
| 2018-08-10 | 1147.50 | 未披露 |
更多>>
1. Common stock offered 3,333,334 shares
2. The number of shares of our common stock to be outstanding immediately following this offering set forth above is based on 8,141,715 shares of our common stock outstanding as of March 31, 2018
3. The 1-for-10 reverse stock split of our common stock effected on August 7, 2018
|
2018-08-09 |
| 2018-07-09 | 1103.27 | 未披露 | 定期报告 | 2018-07-09 |
| 2018-08-14 | 110.33 | 5879.22 |
更多>>
From December 31, 2017 to June 30, 2018
Exercise of stock options
|
2018-06-30 |
| 2018-07-23 | 110.26 | 5879.22 | 定期报告 | 2018-03-31 |
Common stock offered 193,000 shares by the company
Vaccinex, Inc. announced that it will effect a 1-for-14 reverse stock split of its issued common stock, effective at 5:00 p.m. Eastern Time on Monday, February 19, 2024. Beginning Tuesday, February 20, 2024, the Company's common stock will trade on a split-adjusted basis.
Common stock offered 7,600,000 share by the company
From June 30, 2023 to September 30, 2023
Issuance of Common Shares
On September 22, 2023, Vaccinex, Inc. (the “Company”) filed a Certificate of Amendment (the “Amendment”) to the Company’s Amended and Restated Certificate of Incorporation, with the Delaware Secretary of State to implement a reverse stock split of the Company’s issued shares of common stock at a ratio of 1-for-15, effective at 5:00 p.m. Eastern Time on September 25, 2023 (the “Reverse Stock Split”).s
From March 31, 2023 to June 30, 2023
Issuance of Common Shares
From January 1, 2023 to March 31, 2023
Issuance of Common Shares
From December 31, 2021 to December 31, 2022
Issuance of common shares
From March 31, 2021 to June 30, 2021
Exchange of partnership units for common shares
From January 1, 2021 To March 31, 2021
Issuance of Common Shares
Shares issued for compensation
Exchange of VX3 Units for common shares
From December 31, 2019 to December 31, 2020
Issuance of Common Shares
Exchange of Vaccinex Products LP Units for common shares
Stock-based compensation
Exercise of stock options
From June 30, 2020 to September 30, 2020
Issuance of common shares
Exchange of Vaccinex Products LP Units for common shares
Exercise of stock options
From March 31, 2020 to June 30, 2020
Issuance of common shares
Exchange of Vaccinex Products LP Units for common shares
From January 1, 2020 to March 31, 2020
Issuance of Common Shares
Stock-based compensation
Exercise of stock options
from December 31, 2018 to December 31, 2019
Issuance of Common Shares
Conversion of Vaccinex Products LP Units into common shares
from June 30, 2019 to September 30, 2019
Issuance of Common Shares
from March 31, 2019 to June 30, 2019
Conversion of Vaccinex Products LP Units into common shares
from December 31, 2017 to September 30, 2018
Conversion of redeemable convertible preferred stock (Series B, B-1, B-2, C, D) to common stock
Conversion of convertible preferred stock (Series A) to common stock
Initial public offering, net of issuance costs of $5,551
Exercise of stock options
1. Common stock offered 3,333,334 shares
2. The number of shares of our common stock to be outstanding immediately following this offering set forth above is based on 8,141,715 shares of our common stock outstanding as of March 31, 2018
3. The 1-for-10 reverse stock split of our common stock effected on August 7, 2018
From December 31, 2017 to June 30, 2018
Exercise of stock options